Nucleic acids encoding mosaic HIV-1 gag proteins
View Patent ↗The disclosure generally relates to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine, and to methods of using same.
1. A nucleic acid comprising nucleotides encoding a polypeptide selected from the group consisting of SEQ ID NO: 72 (Gag M syn3.1), SEQ ID NO: 73 (Gag M syn3.2) and SEQ ID NO: 74 (Gag M syn3.3).
2. The nucleic acid of claim 1 encoding the polypeptide of SEQ ID NO: 72 (Gag M syn3.1).
3. The nucleic acid of claim 1 encoding the polypeptide of SEQ ID NO: 73 (Gag M syn3.2).
4. The nucleic acid of claim 1 encoding the polypeptide of SEQ ID NO: 74 (Gag M syn3.3).
5. A vector comprising a nucleic acid of claim 1 , wherein the nucleic acid is operably linked to a promoter.
6. The vector of claim 5 , wherein the vector is a viral vector.
7. The vector of claim 6 , wherein the viral vector is an adenoviral vector, an adeno-associated virus vector, a pox virus vector, an enteric virus vector, a Venezuelean Equine Encephalitis Virus vector, a Semliki Forest Virus vector, or a Tobacco Mosaic Virus vector.
8. A composition comprising at least one of the nucleic acids of claim 1 and a carrier.
9. A composition comprising the vector of claim 5 and a carrier.
10. The composition of claim 8 , wherein the composition further comprises an adjuvant.
11. The composition of claim 9 , wherein the composition further comprises an adjuvant.
12. A trivalent composition comprising nucleic acids comprising nucleotides encoding a polypeptide of SEQ ID NO: 72 (Gag M syn3.1), SEQ ID NO: 73 (Gag M syn3.2), and SEQ ID NO: 74 (Gag M syn3.3).
13. The trivalent composition of claim 12 , wherein the composition comprises nucleic acids encoding the polypeptide of SEQ ID NO: 72 (Gag M syn3.1), SEQ ID NO: 73 (Gag M syn3.2) and SEQ ID NO: 74 (Gag M syn3.3).
14. The trivalent composition of claim 12 or 13 , wherein each nucleic acid is operably linked to a promoter in a vector.
15. The trivalent composition of claim 14 , wherein the vector is a viral vector.
16. The trivalent composition of claim 15 , wherein the viral vectors is an adenoviral vector, an adeno-associated virus vector, a pox virus vector, an enteric virus vector, a Venezuelean Equine Encephalitis Virus vector, a Semliki Forest Virus vector, or a Tobacco Mosaic Virus vector.
17. The trivalent composition of claim 12 or 13 further comprising an adjuvant.
18. A method of inducing an immune response against HIV-1 in a host comprising administering to the host the composition of claim 12 or 13 in an amount sufficient to induce the response.